Marc Martinell Pedemonte

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain.

Crystax Pharmaceuticals is the first Spanish biotech dedicated to structure-based drug discovery. Located in Barcelona, Crystax was founded in 2002 by recognized scientists Miquel Coll and Juan Aymamí seeking to apply their structural biology knowledge and experience to the drug discovery process. Its mission is to find the best possible drug in the shortest time and with the highest rate of success. They aim to achieve this mission through its B2D2™ platform and the commitment of its team. Its biophysics based drug discovery platform B2D2™, covers the entire process from target cloning to lead optimization. Through structure determination of target proteins with the fragment hits, they obtain key structural information for the design of new compounds. They also use biophysical characterization to guide the follow-up of the initial hits. The result is an acceleration of the drug discovery process